Miranda Toledano

Chief Executive Officer & Board Member

Therapeutic Areas

Drug	Indication	Phase
EB613 (oral PTH(1-34))	Postmenopausal Osteoporosis	Phase 3 Ready
EB612 (oral PTH(1-34))	Hypoparathyroidism	Phase 2
Oral Oxyntomodulin	Obesity	Discovery/Preclinical
Oral GLP-2	Short Bowel Syndrome	Discovery/Preclinical
Oral Long-Acting PTH	Hypoparathyroidism	Discovery/Preclinical